Hematology
5 drugs are in development for Myelodysplastic Syndromes.
- Companies
- 4
- Clinical trials
- 58
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Myelodysplastic Syndromes pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| EVRENZO (爱瑞卓®) / roxadustat | KYNTRA BIO INC. (KYNB) |
Phase 3(1)
| Drug | Company |
|---|---|
| roxadustat | KYNTRA BIO INC. (KYNB) |
Phase 1(3)
| Drug | Company |
|---|---|
| inkmune | Inmune Bio, Inc. (INMB) |
| MGD024 | MACROGENICS INC (MGNX) |
| sl-172154 | Shattuck Labs, Inc. (STTK) |
About this indication
Myelodysplastic Syndromes context
Hematology·MeSH: Myelodysplastic Syndromes (D009190)
Also known as: Dysmyelopoietic Syndrome, Myelodysplastic Syndrome, Syndromes, Dysmyelopoietic
Prevalence
13.0 / 100K
Incidence
4.6 / 100K/yr
Frequently asked questions
How many drugs are in development for Myelodysplastic Syndromes?
BioSniper tracks 5 drugs in development for Myelodysplastic Syndromes across 4 companies.
How many clinical trials target Myelodysplastic Syndromes?
There are 58 clinical trials targeting Myelodysplastic Syndromes tracked by BioSniper.
What is the prevalence of Myelodysplastic Syndromes?
The estimated prevalence of Myelodysplastic Syndromes is approximately 13.0 per 100,000 population.